Dissolution of arterial platelet thrombi in vivo with a bifunctional platelet GPIIIa49-66 ligand which specifically targets the platelet thrombus
Open Access
- 30 September 2010
- journal article
- Published by American Society of Hematology in Blood
- Vol. 116 (13) , 2336-2344
Abstract
Patients with HIV-1 immune-related thrombocytopenia have a unique antibody (Ab) against integrin GPIIIa49-66 capable of inducing oxidative platelet fragmentation via Ab activation of platelet nicotinamide adenine dinucleotide phosphate oxidase and 12-lipoxygenase releasing reactive oxygen species. Using a phage display single-chain antibody (scFv) library, we developed a novel human monoclonal scFv Ab against GPIIIa49-66 (named A11) capable of inducing fragmentation of activated platelets. In this study, we investigated the in vivo use of A11. We show that A11 does not induce significant thrombocytopenia or inhibit platelet function. A11 can prevent the cessation of carotid artery flow produced by induced artery injury and dissolve the induced thrombus 2 hours after cessation of blood flow. In addition, A11 can prevent, as well as ameliorate, murine middle cerebral artery stroke, without thrombocytopenia or brain hemorrhage. To further optimize the antithrombotic activity of A11, we produced a bifunctional A11-plasminogen first kringle agent (SLK), which homes to newly deposited fibrin strands within and surrounding the platelet thrombus, reducing effects on nonactivated circulating platelets. Indeed, SLK is able to completely reopen occluded carotid vessels 4 hours after cessation of blood flow, whereas A11 had no effect at 4 hours. Thus, a new antithrombotic agent was developed for platelet thrombus clearance.Keywords
This publication has 30 references indexed in Scilit:
- Expansion of the Time Window for Treatment of Acute Ischemic Stroke With Intravenous Tissue Plasminogen ActivatorStroke, 2009
- C-terminal ADAMTS-18 fragment induces oxidative platelet fragmentation, dissolves platelet aggregates, and protects against carotid artery occlusion and cerebral strokeBlood, 2009
- Induction of Toll-Like Receptor 9 Signaling as a Method for Ameliorating Alzheimer's Disease-Related PathologyJournal of Neuroscience, 2009
- Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic strokeNature Medicine, 2008
- Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stroke: Results of an International Phase III TrialStroke, 2008
- Platelet particle formation by anti–GPIIIa49-66 Ab, Ca2+ ionophore A23187, and phorbol myristate acetate is induced by reactive oxygen species and inhibited by dexamethasone blockade of platelet phospholipase A2, 12-lipoxygenase, and NADPH oxidaseBlood, 2007
- Blocking the apolipoprotein E/amyloid-β interaction as a potential therapeutic approach for Alzheimer's diseaseProceedings of the National Academy of Sciences, 2006
- Endovascular Recanalization Therapy in Acute Ischemic StrokeStroke, 2006
- Integrin α IIb β 3 Inhibitor Preserves Microvascular Patency in Experimental Acute Focal Cerebral IschemiaStroke, 2000
- Reduced microvascular thrombosis and improved outcome in acute murine stroke by inhibiting GP IIb/IIIa receptor-mediated platelet aggregation.Journal of Clinical Investigation, 1998